Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics completed enrollment in the Phase 2b BROADEN2 trial evaluating KT-621 in moderate to severe atopic dermatitis. The trial enrolled nearly six months ahead of schedule, moving the topline data readout expectation to year-end 2026 from mid-2027, with Phase 3 trials now planned to initiate by mid-2027.
Key figures
- Drug Name
- KT-621
- Phase Of Trial
- Phase 2b
- Patient count
- 200
- Data readout expected
- year-end 2026
- Treatment duration weeks
- 16
- Phase3 initiation planned
- mid-2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.